



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 21 2001

RECEIVED

#2
N.M.
9/21/01

In re application of

LOUIS, WILLIAM J., et al.

Appln. No. 09/530,807

Group Art Unit: 1626

Confirmation No.: Not Yet Assigned

Examiner: WRIGHT, S.

Filed: May 05, 2000

For: RECEPTOR WITH AN AFFINITY FOR COMPOUNDS OF THE OXAZOLINE
CLASS

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

1. P. Timmermans et al, "Quantitative Relationships between α -Adrenergic Activity and Binding Affinity of α -Adrenoceptor Agonists and Antagonists," J Med Chem, 1984, vol. 27, pages 495-503.
2. P. Timmermans et al, "Characterization of α -Adrenoceptor Populations. Quantitative Relationships between Cardiovascular Effects Initiated at Central and Peripheral α -Adrenoceptors," J Med Chem, 1981, vol, 24, no. 5, pages 502-507.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/530,807

3. V. Deckert et al, "Contribution of α_2 - Adrenoceptors to the Central Cardiovascular Effects of Clonidine and S 8350 in Anaesthetized Rats," Clinical and Experimental Pharmacology and Physiology, (1991) 18, 401-408.
4. A. Hirashima, et al, "Synthesis and Octopaminergic-Agonist Activity of 2-(Arylimino)oxazolidines and 2-(Substituted Benzylamino)-2-oxazolines," Journal of Pesticide Science, 21 (4), November 1996, pages 419-424.
5. PCT International Publication No. WO 95/11021 published April 27, 1995 (International Filing Date: October 20, 1994 PCT/US94/12015).

One copy of each of the listed documents is submitted herewith, along with a copy of the corresponding Communication from a Foreign Patent Office.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date for an application other than a continued prosecution application (CPA) under §1.53(d); (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No. 09/530,807

waive any right to take any action that would be appropriate to antedate or otherwise
remove any listed document as a competent reference against the claims of the present
application.

Respectfully submitted,


Susan J. Mack
Registration No. 30,951

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3213
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: September 19, 2001